Smart Money Is Betting Big In ISRG Options
Morgan Stanley Maintains Intuitive Surgical(ISRG.US) With Hold Rating, Raises Target Price to $522
Analysts Offer Insights on Healthcare Companies: Intra-Cellular Therapies (ITCI), Amylyx Pharmaceuticals Inc (AMLX) and Intuitive Surgical (ISRG)
Earnings Beat: Intuitive Surgical, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Barclays Sticks to Their Buy Rating for Intuitive Surgical (ISRG)
Mizuho Securities Maintains Intuitive Surgical(ISRG.US) With Hold Rating, Raises Target Price to $550
Expand
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}